Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites
Primary Purpose
Liver Cirrhosis
Status
Unknown status
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
small quantity paracentesis
Large Volume Paracentesis
Sponsored by
About this trial
This is an interventional treatment trial for Liver Cirrhosis
Eligibility Criteria
Inclusion Criteria:
- Cirrhotic patients 18-70 yrs with refractory severe ascites with stable renal function (S.creatinine < 2 mg/dl).
Exclusion Criteria:
- CTP >12, MELD>25
- Prior or current Spontaneous Bacterial Peritonitis (SBP)
- Recurrent or current overt hepatic encephalopathy
- Serum Creatinine >2
- HVOTO (Hepatic Venous Outflow Tract Obstruction)
- Hepatic or extrahepatic malignancy
- Recent UGI bleed
- Sepsis
- Serum Sodium < 120
Sites / Locations
- Institute of Liver & Biliary SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Small Quantity Paracentesis
Large Volume Paracentesis
Arm Description
Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
Large Volume Paracentesis > 5 litres
Outcomes
Primary Outcome Measures
Proportion of cirrhotic patients with refractory ascites achieving at least 50 % reduction on need for large volume paracentesis in both groups
Secondary Outcome Measures
Number of participants which requires repeated paracentesis in both groups
Number of participants which requires repeated paracentesis in both groups
Number of participants which requires for repeated paracentesis in both groups
Number of participants with AKI : Improvement or worsening of renal functions in both groups
Number of participants with AKI : Improvement or worsening of renal functions in both groups
Number of participants with AKI : Improvement or worsening of renal functions in both groups
Number of participants with Hepatic Encephalopathy in both groups
Grading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Number of participants with Hepatic Encephalopathy in both groups
Grading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Number of participants with Hepatic Encephalopathy in both groups
Grading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Number of participants with Hyponatremia in both groups
Number of participants with Hyponatremia in both groups
Number of participants with Hyponatremia in both groups
Diuretic tolerability : Dose tolerated in both groups
Diuretic tolerability : Dose tolerated in both groups
Diuretic tolerability : Dose tolerated in both groups
Diuretic tolerability : Duration tolerated in both groups
Diuretic tolerability : Duration tolerated in both groups
Diuretic tolerability : Duration tolerated in both groups
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups
Transplant free survival in both groups
Transplant free survival in both groups
Transplant free survival in both groups
Number of participants develop adverse events associated with procedure in both groups
Number of participants develop adverse events associated with procedure in both groups
Number of participants develop adverse events associated with procedure in both groups
Change in Model for End Stage Liver Disease Score in both groups
MELD Score ranges from 6 to 40
Change in Model for End Stage Liver Disease Score in both groups
MELD Score ranges from 6 to 40
Change in Model for End Stage Liver Disease Score in both groups
MELD Score ranges from 6 to 40
Change in CTP (Child-Turcotte-Pugh) Score in both groups
Child class A: < 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Change in CTP (Child-Turcotte-Pugh) Score in both groups
Child class A: < 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Change in CTP (Child-Turcotte-Pugh) Score in both groups
Child class A: < 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Number of patients required hospitalization between the groups
Number of patients required hospitalization between the groups
Number of patients required hospitalization between the groups
Full Information
NCT ID
NCT04406298
First Posted
May 15, 2020
Last Updated
July 28, 2020
Sponsor
Institute of Liver and Biliary Sciences, India
1. Study Identification
Unique Protocol Identification Number
NCT04406298
Brief Title
Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites
Official Title
Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites- A Randomized Controlled Trial (I-CARE)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 4, 2020 (Actual)
Primary Completion Date
May 20, 2021 (Anticipated)
Study Completion Date
May 20, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to assess the efficacy of intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days in comparison with large volume paracentesis on decreasing the need for repeated paracentesis by 50 % over next 3 months. The project will be conducted at ILBS between April 2020 and March 2021. The concept of the study is to evaluate the efficacy of indwelling catheter in reducing the refilling rates of ascites by 50 % over 3 months in comparison to LVPs and also in reducing the incidence and risk of PPCD. All refractory ascites patients will be included as per inclusion and exclusion criteria, after taking informed consent from the patient or their relatives.
The expected outcomes are
Primary outcome: Proportion of cirrhotic patients with refractory ascites achieving at least 50 % reduction on need for large volume paracentesis after a short duration (5day) intermittent small quantity (up to 3L/ day) paracentesis through an indwelling catheter in comparison to a single large volume paracentesis in the next 3 months.
Secondary outcome:
1. Proportion of cirrhotic patients with refractory ascites developing P 2 . During a 30 D, 60 D and 90 D follow up, to assess between the groups
Need for repeated paracentesis : Number assessed
AKI : Improvement or worsening of renal functions
Hepatic encephalopathy: Grading as per West Haven Classification
Hyponatremia
Diuretic tolerability : Dose and duration tolerated
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm
Transplant free survival
Risk of procedure related complications
Changes in MELD or CTP between the groups ( Improvement vs worsening )
Need for hospitalization between the groups
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cirrhosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Small Quantity Paracentesis
Arm Type
Experimental
Arm Description
Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
Arm Title
Large Volume Paracentesis
Arm Type
Active Comparator
Arm Description
Large Volume Paracentesis > 5 litres
Intervention Type
Procedure
Intervention Name(s)
small quantity paracentesis
Intervention Description
Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
Intervention Type
Procedure
Intervention Name(s)
Large Volume Paracentesis
Intervention Description
Large Volume Paracentesis > 5litres
Primary Outcome Measure Information:
Title
Proportion of cirrhotic patients with refractory ascites achieving at least 50 % reduction on need for large volume paracentesis in both groups
Time Frame
3 Months
Secondary Outcome Measure Information:
Title
Number of participants which requires repeated paracentesis in both groups
Time Frame
30 days
Title
Number of participants which requires repeated paracentesis in both groups
Time Frame
60 days
Title
Number of participants which requires for repeated paracentesis in both groups
Time Frame
90 days
Title
Number of participants with AKI : Improvement or worsening of renal functions in both groups
Time Frame
30 days
Title
Number of participants with AKI : Improvement or worsening of renal functions in both groups
Time Frame
60 days
Title
Number of participants with AKI : Improvement or worsening of renal functions in both groups
Time Frame
90 days
Title
Number of participants with Hepatic Encephalopathy in both groups
Description
Grading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Time Frame
30 days
Title
Number of participants with Hepatic Encephalopathy in both groups
Description
Grading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Time Frame
60 days
Title
Number of participants with Hepatic Encephalopathy in both groups
Description
Grading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Time Frame
90 days
Title
Number of participants with Hyponatremia in both groups
Time Frame
30 days
Title
Number of participants with Hyponatremia in both groups
Time Frame
60 days
Title
Number of participants with Hyponatremia in both groups
Time Frame
90 days
Title
Diuretic tolerability : Dose tolerated in both groups
Time Frame
30 days
Title
Diuretic tolerability : Dose tolerated in both groups
Time Frame
60 days
Title
Diuretic tolerability : Dose tolerated in both groups
Time Frame
90 days
Title
Diuretic tolerability : Duration tolerated in both groups
Time Frame
30 days
Title
Diuretic tolerability : Duration tolerated in both groups
Time Frame
60 days
Title
Diuretic tolerability : Duration tolerated in both groups
Time Frame
90 days
Title
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups
Time Frame
30 days
Title
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups
Time Frame
60 days
Title
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups
Time Frame
90 days
Title
Transplant free survival in both groups
Time Frame
30 days
Title
Transplant free survival in both groups
Time Frame
60 days
Title
Transplant free survival in both groups
Time Frame
90 days
Title
Number of participants develop adverse events associated with procedure in both groups
Time Frame
30 days
Title
Number of participants develop adverse events associated with procedure in both groups
Time Frame
60 days
Title
Number of participants develop adverse events associated with procedure in both groups
Time Frame
90 days
Title
Change in Model for End Stage Liver Disease Score in both groups
Description
MELD Score ranges from 6 to 40
Time Frame
30 days
Title
Change in Model for End Stage Liver Disease Score in both groups
Description
MELD Score ranges from 6 to 40
Time Frame
60 days
Title
Change in Model for End Stage Liver Disease Score in both groups
Description
MELD Score ranges from 6 to 40
Time Frame
90 days
Title
Change in CTP (Child-Turcotte-Pugh) Score in both groups
Description
Child class A: < 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Time Frame
30 days
Title
Change in CTP (Child-Turcotte-Pugh) Score in both groups
Description
Child class A: < 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Time Frame
60 days
Title
Change in CTP (Child-Turcotte-Pugh) Score in both groups
Description
Child class A: < 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Time Frame
90 days
Title
Number of patients required hospitalization between the groups
Time Frame
30 days
Title
Number of patients required hospitalization between the groups
Time Frame
60 days
Title
Number of patients required hospitalization between the groups
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Cirrhotic patients 18-70 yrs with refractory severe ascites with stable renal function (S.creatinine < 2 mg/dl).
Exclusion Criteria:
CTP >12, MELD>25
Prior or current Spontaneous Bacterial Peritonitis (SBP)
Recurrent or current overt hepatic encephalopathy
Serum Creatinine >2
HVOTO (Hepatic Venous Outflow Tract Obstruction)
Hepatic or extrahepatic malignancy
Recent UGI bleed
Sepsis
Serum Sodium < 120
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Manasa Alla, MD
Phone
01146300000
Email
manasa1512@gmail.com
Facility Information:
Facility Name
Institute of Liver & Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Manasa Alla, MD
Phone
01146300000
Email
manasa1512@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites
We'll reach out to this number within 24 hrs